Ramdev, Balkrishna Acharya Ready For ‘Public Apology’; Supreme Court Next Hearing On April 23

New Delhi: The Supreme Court on Tuesday granted a week to Yoga guru Ramdev and Patanjali Ayurved Ltd MD Balkrishna Acharya to take steps to redeem themselves of the alleged contempt after their lawyers offered to issue a public apology for misleading advertisements.

“I am willing to give a public apology,” senior advocate Mukul Rohatgi, appearing for Ramdev and Balkrishna, told a bench of Justices Hima Kohli and Ahsanuddin Amanullah, news agency PTI reported.

The Supreme Court court asked Ramdev and Balkrishna, both of whom were present in the court, to come forward for an interaction with the bench.

“They should feel they have a connect with the court,” the bench said.

The hearing in the matter is underway and the bench is currently interacting with Ramdev.

Ramdev and Balkrishna have tendered an “unconditional and unqualified apology” before the apex court over advertisements issued by the firm making tall claims about the medicinal efficacy of its products.

In two separate affidavits filed in the court, Ramdev and Balkrishna have tendered an unqualified apology for the “breach of the statement” recorded in the November 21 last year order of the apex court.

In the November 21, 2023 order, the top court had noted that counsel representing Patanjali Ayurved had assured it that “henceforth there shall not be any violation of any law(s), especially relating to advertising or branding of products manufactured and marketed by it and, further, that no casual statements claiming medicinal efficacy or against any system of medicine will be released to the media in any form”.

The top court had said Patanjali Ayurved Ltd is “bound down to such assurance”.

The non-observance of the specific assurance and the subsequent media statements irked the apex court, which later issued a notice to them to explain why contempt proceedings be not initiated against them.

Related Posts

  • Pharma
  • July 26, 2024
  • 123 views
US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

Maryland: The US Food and Drug Administration (FDA) has warned Brassica Pharma for numerous good manufacturing practice (GMP) violations, including multiple instances of employees falsifying sterility and environmental monitoring data and…

  • Pharma
  • July 26, 2024
  • 117 views
Indian National Charged With Selling Counterfeit Cancer Drugs

HOUSTON: A federal grand jury has returned an indictment charging an Indian national with selling and shipping tens of thousands of dollars in counterfeit oncology pharmaceuticals into the United States,…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

Indian National Charged With Selling Counterfeit Cancer Drugs

Indian National Charged With Selling Counterfeit Cancer Drugs

ICMR Releases 32 New Treatment Standards For Treating Common And Serious Diseases

ICMR Releases 32 New Treatment Standards For Treating Common And Serious Diseases

BIS Sanctioned 82 Medical Device Projects To Develop Standards

BIS Sanctioned 82 Medical Device Projects To Develop Standards

Anti-Narcotics Task Force Will Be Formed Soon In Rajasthan: HM

Anti-Narcotics Task Force Will Be Formed Soon In Rajasthan: HM

‘Sunrise’ MedTech Industry in India & ‘Clouds’ strangling it, Brainstormed in PHD

‘Sunrise’ MedTech Industry in India & ‘Clouds’ strangling it, Brainstormed in PHD